Chromium News and Research

RSS

Chromium is among the minerals – zinc and magnesium are others – which the body requires to keep itself in the best of health and to function best physiologically. Humans need trace amounts of chromium. Those who are very active definitely require chromium and other minerals in their diets so that they can be sure they are able to sustain increased levels of energy and work.

Svelte initiates Rapamycin-eluting stent with bio-Eroding Carrier Technology implantation study

Svelte Medical Systems today announced treatment of the first patient in the DIRECT (Direct-on-a-wire Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study at Auckland City Hospital in Auckland, New Zealand.

9 Nov 2011

Boston Scientific reports positive long-term data from PERSEUS clinical program

Boston Scientific Corporation reports positive long-term data from the PERSEUS clinical program, which demonstrated favorable two-year safety and effectiveness outcomes for the ION (TAXUS Element) Paclitaxel-Eluting Platinum Chromium Stent System versus prior-generation paclitaxel-eluting stents.

9 Nov 2011

FDA approves Abbott's XIENCE PRIME Everolimus Eluting Coronary Stent System

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the next-generation XIENCE PRIME Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease.

2 Nov 2011

FDA approves Medtronic's Assurant Cobalt stent to treat narrowed iliac arteries

Advancing the treatment of peripheral artery disease, Medtronic, Inc. today announced approval by the U.S. Food and Drug Administration (FDA) of the Assurant Cobalt Iliac Balloon-Expandable Stent System.

From Medtronic 1 Nov 2011

University of Kentucky receives Department of Defense grant for lung cancer study

The University of Kentucky's Dr. Susanne Arnold and colleagues were awarded a grant by the Department of Defense to study potential environmental reasons for the high lung cancer rates in Eastern Kentucky.

23 Sep 2011

Xience V stent performs well in patients with primary PCI for ST elevation myocardial infarction

The second generation drug-eluting stent Xience V performs well in patients having primary PCI for ST elevation myocardial infarction, and has a better safety profile than that of bare metal stents, according to results of the EXAMINATION trial.

30 Aug 2011

FDA approves Abbott's RX Herculink Elite Renal Stent System for renal artery stenosis

Abbott today announced it has received U.S. Food and Drug Administration (FDA) approval for the RX Herculink Elite® Renal Stent System for the treatment of renal artery stenosis (narrowing of the main arteries supplying blood to the kidneys) in patients with uncontrolled hypertension (high blood pressure).

10 Aug 2011

Pipeline Embolization Device safe and effective for patients with brain aneurysms

Physicians at Rush University Medical Center are offering a new and effective treatment to patients suffering from complex brain aneurysms. The recently FDA-approved technology called the Pipeline Embolization Device (PED) gives doctors the ability for the very first time to treat some of the most complex and dangerous brain aneurysms using minimally invasive techniques.

3 Jun 2011

FDA approves Abbott's XIENCE nano stent for treatment of coronary artery disease in small vessels

Abbott today announced it has received U.S. Food and Drug Administration approval for the XIENCE nano Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease in small vessels.

25 May 2011

Boston Scientific launches Expect Endoscopic Ultrasound Aspiration Needle

Boston Scientific Corporation today announced the U.S. and international launch of its Expect™ Endoscopic Ultrasound Aspiration Needle, used for acquiring tissue samples for diagnosing and staging malignancies in organs adjacent to the gastrointestinal tract. The Expect Needle received FDA clearance and CE Mark approval earlier this year and is being marketed in the U.S., Europe and other international markets.

9 May 2011

Boston Scientific launches ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System

Boston Scientific Corporation today announced U.S. Food and Drug Administration (FDA) approval and launch of the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System, the Company's third-generation drug-eluting stent technology.

25 Apr 2011

FDA approval of Pipeline Embolization Device offers better options for treatment of large/giant aneurysms

The recent U.S. Food and Drug Administration (FDA) approval of a brain aneurysm device has opened the door for neurosurgeons at Jefferson Hospital for Neuroscience (JHN) to offer advanced treatment to patients suffering from large or giant aneurysms who otherwise have limited, effective options.

19 Apr 2011

New Pipeline Embolization Device receives FDA approval for treatment of brain aneurysms

The U.S. Food and Drug Administration today approved a new device that provides neurointerventional surgeons with another tool to treat brain aneurysms without performing open surgery.

7 Apr 2011

BSX presents ION and TAXUS Stent trial data against coronary artery disease at ACC meeting

Boston Scientific Corporation today announced results from a pooled patient-level analysis of its PERSEUS and TAXUS ATLAS clinical trial data, demonstrating differences in safety and efficacy outcomes favoring the next-generation ION Platinum Chromium Paclitaxel-Eluting Stent System compared to the currently available TAXUS Liberte Paclitaxel-Eluting Stent System.

4 Apr 2011

OrbusNeich launches CE marked Azule Cobalt Chromium Stent

OrbusNeich today announced the launch of the CE marked Azule Cobalt Chromium Stent. The Azule Stent combines the proven stent design of its predecessor, the company's Blazer™ Cobalt Chromium Stent, with a delivery system with enhanced crossability and flexible deliverability.

14 Mar 2011

Micell initiates enrollment in DESSOLVE II MiStent Drug-Eluting Coronary Stent System trial

Micell Technologies,™ Inc. today announced it has enrolled the first patient in the DESSOLVE II (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries) clinical trial. Stefan Verheye, M.D., Ph.D. at Middelheim Hospital, Antwerp, Belgium enrolled the first patient in the study. This clinical investigation is being conducted to support CE Mark approval of the company's MiStent™ Drug-Eluting Coronary Stent System (MiStent DES).

18 Feb 2011

AAOS appreciates FDA's communication on metal-on-metal hip components in total hip arthroplasty

The U.S. Food and Drug Administration (FDA) today posted a public health communication about metal-on-metal hip components used in total hip arthroplasty (THA). The American Academy of Orthopaedic Surgeons (AAOS) appreciates this thorough and well-considered look at the concerns surrounding the use of these implants.

11 Feb 2011

Natural menopause remedies containing chromium picolinate prevent weight gain

Natural menopause cures can help a woman with weight gain that can occur during menopause. The changes that are going on inside a woman's body can cause weight gain, especially around the hips, stomach and thighs. Natural menopause remedies that contain chromium picolinate have been beneficial in helping women to avoid this weight gain during menopause.

4 Feb 2011

Boston Scientific initiates enrollment in comparative Chinese study of PROMUS Element Everolimus-Eluting Stent

Boston Scientific Corporation today announced the beginning of patient enrollment in the PLATINUM China clinical trial, which is designed to evaluate the safety and effectiveness of the Company's PROMUS Element™ Everolimus-Eluting Platinum Chromium Coronary Stent compared to the TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent in the treatment of patients with a single de novo atherosclerotic lesion.

27 Jan 2011

Boston Scientific completes enrollment in comparison trial of SYNERGY Stent to PROMUS Element Stent

Boston Scientific Corporation today announced the completion of patient enrollment in the EVOLVE clinical trial, which is designed to assess the safety and performance of the Company's fourth-generation SYNERGY™ Coronary Stent. The randomized, single-blind, non-inferiority trial will compare the SYNERGY Stent to the PROMUS Element™ Everolimus-Eluting Coronary Stent in patients with a single de novo native coronary artery lesion.

24 Jan 2011